

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

POSITIVE PROFIT ALERT

This announcement is published by Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to the Inside Information Provisions under of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The board of directors of the Company (the “**Board**”) hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ending 30 June 2021 (the “**Reporting Period**”), the Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB220,000,000 to RMB250,000,000 during the Reporting Period, representing an increase of approximately RMB192,472,800 to RMB222,472,800, or approximately 699.21% to 808.19%, as compared to that in 2020 (corresponding period in 2020: an unaudited net profit attributable to shareholders of the Company of RMB27,527,226.38). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB210,000,000 to RMB240,000,000, representing an increase of approximately RMB202,170,100 to RMB232,170,100, or approximately 2,582.03% to 2,965.17%, as compared to that in 2020 (corresponding period in 2020: unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB7,829,874.35).

As far as the Board is aware, the profit growth for the Reporting Period as compared to the corresponding period in 2020 was mainly due to the significant impact of the COVID-19 pandemic (the “**Pandemic**”) on the sales of the Group’s major products in the first half of 2020, and the recovery and growth in domestic market demand for the Group’s main products during the Reporting Period as a result of the effective control of the Pandemic and the recovery of the economy in China. Meanwhile, the Group continued to carry out all kinds of sales and marketing activities to expand brand awareness and influence. During the Reporting Period, the sales of the Group’s products, especially new products, increased considerably compared with the corresponding period in 2020.

The Board hereby reminds the Shareholders and potential investors of the Company that the information set out in this announcement is based on an assessment with reference to the information currently available to the Group and has not been reviewed by the audit committee of the Company and the independent auditors. The Group is still finalizing the unaudited results for the six months ending 30 June 2021 (the “**Interim Results**”), which are subject to adjustments (if necessary). The Interim Results may differ from the data set out in this announcement. Shareholders and potential investors of the Company are advised to read carefully the details of the Group’s Interim Results, which is expected to be published in late August 2021.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, 25 June 2021

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Ms. Li Yingqi, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.

* *For identification purpose only*